

## ASX Release

### COMPLETION OF NEWLY ACQUISITION

Novita Healthcare Limited (ASX: NHL) (“**Novita**” or the “**Company**”), is pleased to advise that it has today, 21 July 2017, completed the acquisition of Newly Pty Ltd (“**Newly**”).

Details of the Newly acquisition were provided in the Company’s ASX announcements on 12 July 2017, the Offer Document lodged with ASX on 13 July and the Notice of General Meeting lodged with ASX on 19 July 2017.

As part of the settlement consideration the Company advises that 30,689,095 new shares have been issued under the Company’s unconditional placement capacity under ASX Listing Rule 7.1, and as disclosed in the Appendix 3B lodged with ASX on 14 July 2017.

### TRANSACTION SUMMARY

The final consideration paid for Newly comprises:

- An upfront purchase consideration of \$920,673 (being agreed purchase price less settlement adjustments) in fully paid ordinary shares in Novita at an issue price of \$0.03 (being the same issue price as the recent equity placement). The new shares issued are subject to an 18-month escrow period from the date of issue.
- Deferred earn-out payment of 4x profit before tax for CY2019. If applicable, this earn-out is to be paid in cash on 1 March 2020. Parties have retained the discretion to vary the cash payment to facilitate payment of part or all of the earn-out in fully paid ordinary shares in Novita.

Completion of the acquisition of Newly is effective today.

### ABOUT NOVITA

Novita Healthcare is a Melbourne-based health technology company with a long history of innovation, development and commercialisation of medical treatments. Novita Healthcare’s flagship program is the revolutionary and innovative TALI system, which uses cutting edge technology to treat and monitor cognitive problems such as attention difficulties in early childhood.

### CONTACTS

**General:**

**Iain Kirkwood**

Executive Chairman

Novita Healthcare

P: 1300 082 013

E: [novita@novitahealthcare.com.au](mailto:novita@novitahealthcare.com.au)

**Investors:**

**James Barber**

Executive Director

Vesparum Capital

P: (03) 8582 4800

E: [novitahealthcare@vesparum.com](mailto:novitahealthcare@vesparum.com)